BLFS: BioLife Solutions, Inc. Stock

by  •  • Comments Off on BLFS: BioLife Solutions, Inc. Stock

SIC 3845 – Electromedical and Electrotherapeutic Apparatus

Valuation
Market Cap ($M) 1,029.13
Enterprise Value ($M) 948.71
Book Value ($M) 348.91
Book Value / Share 7.44
Price / Book 2.95
NCAV ($M) 98.18
NCAV / Share 2.09
Price / NCAV 10.48

Profitability (mra)
Return on Invested Capital (ROIC) -0.05
Return on Assets (ROA) -0.05
Return on Equity (ROE) -0.06

Liquidity (mrq)
Quick Ratio 3.66
Current Ratio 4.54

Balance Sheet (mrq) ($M)
Current Assets 148.76
Assets 399.49
Liabilities 50.58
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 82.25
Operating Income -7.13
Net Income -20.18
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 8.43
Cash from Investing 58.30
Cash from Financing -6.78

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-09 13D/A Casdin Capital, LLC 18.50 0.32
11-08 13G Invesco Ltd. 7.00
11-01 13G/A Goldman Sachs Group Inc 0.40 -93.48

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-04-08 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A Amendment No. 1
2025-03-03 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT PURSUANT T
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PURSUANT TO SEC
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT PURSUANT TO SE

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-06 284,509 1,134,882 25.07
2025-05-05 103,982 415,281 25.04
2025-05-02 67,306 201,705 33.37

(click for more detail)

Similar Companies
BBLG – Bone Biologics Corporation BEAT – HeartBeam, Inc.
BJDX – Bluejay Diagnostics, Inc. BSGM – BioSig Technologies, Inc.
CHEK – Check-Cap Ltd.


Financial data and stock pages provided by
Fintel.io